Clinical analysis of fatty liver caused by non-Hodgkin lymphoma chemotherapy

Yilin Zhang,Wanhong Zhao,Wanggang Zhang,Aili He,Xingmei Cao,Jie Liu,Yinxia Chen,Jianli Wang,Sheping Chen,Yun Yang,Xiaorong Ma,Liufang Gu,Jin Wang
DOI: https://doi.org/10.3969/j.issn.1672-4992.2018.24.029
2018-01-01
Journal of Modern Oncology
Abstract:Objective:To investigate the incidence and risk factors of fatty liver caused by non-Hodgkin lympho-ma chemotherapy.Methods:From January 2014 to December 2015,our department carried out clinical researches on 158 patients with non-Hodgkin lymphoma,analyze the changes of liver ultrasound and laboratory biochemical indica-tors[ALT(alanine transaminase),AST(aspartate transaminase),CHOL(cholesterol),TG(triglyceride),HDL(high density lipoprotein),LDL (low densith lipoprotein)] before and after chemotherapy. Results:59 of 158 patients showed fatty liver after chemotherapy,the incidence was 37.3%. The occurrences of fatty liver were 1.5 to 17.0 months after chemotherapy,the average of which was 5.4 months,and it occurred after 2.0 to 12.0 chemotherapy courses with the average of 4.2.In the patients with fatty liver,the weight was increased -7.1 to 23.2 kg with the average of 5.5 kg from initial to the diagnosis of fatty liver.There was no significant difference in the incidence of fatty liver between different genders,ages and lymphoma types.The laboratory biochemical indicators had varying degrees of raises and showed significant difference before and after chemotherapy.The livers of 11 fatty liver patients recovered normal in 3 to 9 months after all the chemotherapy completed.Conclusion:The patients of non-Hodgkin lymphoma can develop hepatic dysfunction and dyslipidemia after chemotherapy,and can cause the fatty liver.As clinicians,we should recognize the risk of fatty liver and deal with it earlier.
What problem does this paper attempt to address?